



NEWS RELEASE

# Savara Announces Participation in Upcoming Investor Healthcare Conferences

2025-11-03

LANGHORNE, Pa.--(BUSINESS WIRE)-- **Savara Inc.** (Nasdaq: **SVRA**) (the "Company"), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and participate in fireside chats at two upcoming healthcare conferences.

## Fireside Chats:

### Guggenheim 2<sup>nd</sup> Annual Healthcare Innovation Conference

November 10, 2025, 8:30 a.m. ET

### Jefferies London Healthcare Conference

November 19, 2025, 12:00 p.m. GMT

The live webcasts and subsequent replays will be available on the "**Events & Presentations**" section of the Company's corporate website and will be archived for 90 days.

## About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI\*, is a recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is delivered via a proprietary investigational eFlow<sup>®</sup> Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of MOLBREEVI. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and



commercialization. More information can be found at [www.savarapharma.com](http://www.savarapharma.com) and [LinkedIn](#).

\*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication. MOLBREEVI is a trademark of Savara Inc.

### Media and Investor Relations Contact

Savara Inc.

Temre Johnson, Executive Director, Corporate Affairs

[\*\*ir@savarapharma.com\*\*](mailto:ir@savarapharma.com)

Source: Savara Inc.